Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Plan

Vaxcyte CEO Grant Pickering sold a total of 2,366 shares of common stock on December 9, 2024, through a pre-arranged 10b5-1 trading plan.

Summary

• Grant Pickering, CEO of Vaxcyte, Inc., sold a total of 2,366 shares of common stock on December 9, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 12, 2024.
• The shares were sold at varying weighted-average prices, ranging from $92.032 to $93.598.
• The sales were made in multiple transactions, with the shares being held indirectly through trusts for the benefit of his children.
• Following these transactions, Mr. Pickering directly owns 450,301 shares and indirectly owns 136,215 shares through his children's trusts.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding stock sales by an executive under a pre-arranged plan, which is neither positive nor negative in itself.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although these sales were pre-planned.

Industry Context

Executive stock sales are a common occurrence, and the use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any non-public information.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice for executives to sell shares without raising concerns about insider trading.
• Many executives at publicly traded companies, such as those in the biotechnology sector like Moderna or BioNTech, utilize similar plans for their stock transactions.

Stakeholder Impact

• The stock sales may have a minor impact on the share price, but the pre-planned nature of the sales should mitigate any significant negative reaction from shareholders.

Key Dates

Keywords

Vaxcyte, Grant Pickering, stock sale, Form 4, 10b5-1 plan, executive stock, insider trading